Analytical Data
-
Gene name
HLA-A*02:03&B2M&AFP(FMNKFIYEI) Tetramer
- Application
-
Alternative Names
Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA03604.1 (G25-T305)&P61769
-
Expression Region
AAA03604.1 (G25-T305)&P61769 (I21-M119)&FMNKFIYEI
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*01:01 & B2M & CT83 (NTDNNLAVY) monomeric recombinant protein is significant in the field of immunology and cancer research. HLA-A*01:01 is a major histocompatibility complex (MHC) class I molecule, which plays a crucial role in presenting endogenous peptides, including tumor-specific antigens, to CD8+ cytotoxic T cells. The CT83 antigen, derived from the tumor-associated antigen CT83, is of particular interest due to its potential as a target for immunotherapy in cancers. The peptide NTDNNLAVY, presented by HLA-A*01:01, has been identified as a strong candidate for T cell recognition, making it a vital component in developing therapeutic vaccines or T cell-based treatments. Recombinant production of this protein allows for detailed characterization and analysis, enabling researchers to understand its binding affinity, stability, and immunogenicity. This knowledge aids in designing targeted therapies that can enhance the immune response against CT83-expressing tumors. Ultimately, this research contributes to the broader goal of improving cancer immunotherapy and offers potential pathways for more effective treatments against various malignancies.
